Faecal calprotectin is not a glamorous longevity biomarker. It is a stool test, built for a narrow clinical job: finding signs of gut inflammation when symptoms alone cannot separate irritable bowel syndrome from inflammatory bowel disease. Used well, it can spare some people unnecessary procedures and push others towards the right specialist care. Used badly, it becomes another number to worry over.
What the test is actually measuring
Calprotectin is a protein found mainly in neutrophils, the immune cells that arrive early when tissue is inflamed. When the lining of the gut is inflamed, more of that protein can pass into stool, where a laboratory can measure it. That is the biological logic of the test: it does not measure pain, bloating, microbiome quality, food tolerance, or general health. It measures one signal that tends to rise when there is intestinal inflammation.
The clinical case for the test is strongest in a familiar diagnostic problem. Crohn’s disease, ulcerative colitis, and irritable bowel syndrome can all produce abdominal pain, diarrhoea, urgency, and disrupted routines. The symptoms overlap, but the underlying biology does not. IBD is inflammatory. IBS is usually not. NICE guidance on faecal calprotectin testing describes the test as a tool for distinguishing inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, from non-inflammatory bowel disorders, such as IBS.
Where the evidence is clearest
The best use case is not a healthy person shopping for reassurance. It is a person with recent, persistent lower gastrointestinal symptoms where a clinician is deciding whether specialist investigation is needed. In that setting, faecal calprotectin helps answer a practical question: is there enough evidence of inflammation to make IBD more likely?
A 2023 meta-analysis in Alimentary Pharmacology & Therapeutics found faecal calprotectin reliable for distinguishing IBD from IBS in adults, though performance varied by cut-off and clinical setting. Much of the underlying research came from gastrointestinal clinics and referral centres rather than unselected primary-care populations. When results sit near the decision threshold, repeat testing is often more informative than treating one borderline value as definitive.
That nuance matters because the test is often most useful when it is negative. A low result, in the right clinical context, makes significant gut inflammation less likely. That can support a diagnosis of IBS, or at least make urgent inflammatory disease less probable. A high result does not diagnose Crohn’s disease or ulcerative colitis by itself. It says inflammation is plausible enough to look further.
A number is not a diagnosis
The problem with biomarkers is that numbers look more definitive than they are. Faecal calprotectin is usually reported as a concentration in stool, often in micrograms per gram. Laboratories and local pathways may use different thresholds, and the same result can mean different things depending on age, symptoms, medication, and recent infection.
The Cleveland Clinic’s 2026 patient guide to the fecal calprotectin test puts the interpretation plainly: high levels suggest intestinal inflammation and can point towards IBD, but infection, coeliac disease, diverticulitis, peptic ulcer disease, microscopic colitis, and other conditions can also be involved. That is why the next step after a raised result is clinical judgement, not self-diagnosis.
There is also the matter of false reassurance. A normal value makes active inflammation less likely, but it does not explain every symptom, and it does not overrule red flags such as rectal bleeding, unexplained weight loss, anaemia, fever, or symptoms that wake someone from sleep. Those are not wellness-tracking signals. They are reasons to be assessed properly.
Why clinicians use it before colonoscopy
Colonoscopy remains central to diagnosing and staging IBD, but it is invasive, resource-heavy, and not something to use casually. Faecal calprotectin sits earlier in the pathway. It can help decide who is more likely to benefit from referral and endoscopic assessment, and who may be managed differently while symptoms are monitored.
This is where the test earns its place. It is non-invasive, relatively straightforward, and closer to gut inflammation than a general blood marker such as CRP. That does not make it superior to colonoscopy; it makes it useful before colonoscopy. The distinction is important. A screening or triage test is judged by whether it improves the next decision, not by whether it replaces the final diagnostic work-up.
That pattern holds across much of the literature: useful, especially for ruling out inflammatory disease in selected patients, but not clean enough to interpret without context. Performance depends on the cut-off used, the pre-test probability, and whether the patient is being assessed in primary or specialist care.
Monitoring IBD is a different question
Once someone already has Crohn’s disease or ulcerative colitis, faecal calprotectin can take on a second role. It may help monitor disease activity, treatment response, or the risk that inflammation is returning before symptoms become obvious. This is appealing because symptoms and inflammation do not always move together. A patient can feel better while mucosal inflammation persists, and symptoms can flare for reasons that are not active IBD.
The evidence is promising, but the question is narrower than many consumer conversations suggest. Monitoring is not the same as diagnosis. It is usually done in people with known disease, under a treatment plan, with prior results for comparison. A single isolated value is less helpful than a trend: falling after treatment, rising during remission, or staying unexpectedly high despite symptom improvement.
A systematic review on faecal calprotectin monitoring in asymptomatic IBD reported that two consecutively elevated values were associated with disease relapse, while noting that more prospective data were needed to show whether acting on monitoring improves outcomes. That is a sober conclusion. The test may give an earlier warning; it does not automatically tell the clinician what to change.
What can push the result around
Faecal calprotectin is closer to bowel inflammation than many blood tests, but it is not specific to IBD. Gastrointestinal infection can raise it. Non-steroidal anti-inflammatory drugs can affect results. Some people with borderline values settle on repeat testing. Age, assay type, and local laboratory cut-offs also matter.
This is why the grey zone is so clinically important. A very low value and a very high value are easier to act on. Borderline results are not failures; they are signals that need time, repeat testing, or additional information. NICE guidance on faecal calprotectin testing allows repeat testing when an initial result is borderline, reflecting that slightly raised values may settle while low-grade inflammatory disease may become clearer over time. Trend and clinical picture matter more than a single number held in isolation.
There is also an unhelpful cultural drift around gut testing. A faecal calprotectin result does not score the microbiome, detect food intolerance, prove leaky gut, or validate a supplement routine. It is a clinical marker of intestinal inflammation. That narrower framing is not a weakness. It is what makes the test useful.
What this means in practice
- If you have persistent diarrhoea, abdominal pain, urgency, rectal bleeding, weight loss, fever, or anaemia, treat this as a medical assessment question, not a home-tracking project.
- Use faecal calprotectin for the problem it was built for: helping distinguish inflammatory bowel disease from non-inflammatory causes when symptoms overlap.
- Do not interpret a raised result as a diagnosis of Crohn’s disease or ulcerative colitis. It is a reason to discuss next steps, often including repeat testing or referral.
- Ask what threshold your laboratory or local pathway uses, because cut-offs are not always identical across systems.
- If you already have IBD, look for trends over time rather than treating one result as a verdict on treatment success or failure.
- Tell your clinician about NSAID use, recent infections, new medications, and red-flag symptoms before drawing conclusions from the number.
What we don’t know
The unresolved questions are not about whether faecal calprotectin is useful. It is. The harder questions are about how best to use it across different health systems, thresholds, ages, and disease patterns. Primary-care populations differ from specialist clinic populations. Ulcerative colitis and Crohn’s disease can behave differently. A cut-off that is good for avoiding missed IBD may also send more people for colonoscopy who do not ultimately need it.
There is also a difference between predicting inflammation and improving outcomes. In IBD monitoring, rising calprotectin may detect relapse risk earlier than symptoms alone, but the clinical benefit depends on what happens next: repeat testing, imaging, endoscopy, medication adjustment, or watchful waiting. A biomarker is only as useful as the decision it improves.
Faecal calprotectin deserves its place because it answers one grounded question: is there evidence of intestinal inflammation that should change the next clinical step? That is enough. It does not need to become a gut-health score, a longevity dashboard tile, or a diagnosis in disguise.
Photo: National Cancer Institute / Daniel Sone on Unsplash.